A detailed history of Price T Rowe Associates Inc transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 15,479 shares of TCRX stock, worth $32,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,479
Previous 12,301 25.84%
Holding current value
$32,505
Previous $62,000 22.58%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$2.93 - $5.94 $9,311 - $18,877
3,178 Added 25.84%
15,479 $48,000
Q2 2024

Aug 14, 2024

BUY
$5.85 - $9.51 $71,960 - $116,982
12,301 New
12,301 $0

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $39.8M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.